StemCell Therapy

Global Genetic Leukemia Detection Testing market size will reach xx million US$ by 2025, from xx million US$ in 2018, at a CAGR of xx% during the forecast period. In this study, 2018 has been considered as the base year and 2019-2025 as the forecast period to estimate the market size for Genetic Leukemia Detection Testing .

This industry study presents the global Genetic Leukemia Detection Testing market size, historical breakdown data (2014-2019) and forecast (2019-2025). The Private Plane production, revenue and market share by manufacturers, key regions and type; The consumption of Genetic Leukemia Detection Testing market in volume terms are also provided for major countries (or regions), and for each application and product at the global level.

Request Sample Report @ https://www.futuremarketinsights.co/reports/sample/REP-GB-6733

Global Genetic Leukemia Detection Testing market report coverage:

The Genetic Leukemia Detection Testing market report covers extensive analysis of the market scope, structure, potential, fluctuations, and financial impacts. The report also enfolds the precise evaluation of market size, share, product & sales volume, revenue, and growth rate. It also includes authentic and trustworthy estimations considering these terms.

The Genetic Leukemia Detection Testing market has been reporting substantial growth rates with considerable CAGR for the last couple of decades. According to the report, the market is expected to grow more vigorously during the forecast period and it can also influence the global economic structure with a higher revenue share. The market also holds the potential to impact its peers and parent market as the growth rate of the market is being accelerated by increasing disposable incomes, growing product demand, changing consumption technologies, innovative products, and raw material affluence.

The following manufacturers are covered in this Genetic Leukemia Detection Testing market report:

Key Players

Examples of some of the key players identified in the genetic leukemia detection testing market are Thermofisher Scientific, Creative Diagnostics, Vector Labs, TCS Biosciences Ltd., Alchem Diagnostics, Vela Diagnostics, Beckman Coulter, ELItechGroup.

Market Segmentation

By Test Type

By Product

By End User

By Region

Key Data Points Covered in the Report

The report covers exhaustive analysis on:

Report Highlights:

Research Methodology

The market sizing of genetic testing leukemia kits will be done by adoption data triangulation approach. Demand-side approach will be followed to assess the actual market size of genetic testing leukemia kits. Secondary research will be done at the initial phase to identify the feasibility of the target products/technology categories and its respective segments, product and service offerings, in end-use facilities, adoption rate and future impact of new technologies. Additionally, per capita consumption of syringes, among end users will be tracked at a granular level to obtain the most accurate information. Each piece of information will be eventually analyzed during the entire research project, which helps build a strong base for the primary research information.

Primary research participants include demand-side respondents such as laboratory managers, procurement managers, research supervisors, as well as key opinion leaders in addition to supply-side respondents such as equipment manufacturers, custom solution and service providers who provide valuable insights on trends, research application of products and technologies, purchasing patterns, services offered and associated pricing.

NOTE All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Request Methodology On This Report @ https://www.futuremarketinsights.co/askus/REP-GB-6733

The study objectives are Genetic Leukemia Detection Testing Market Report:

We offer tailor-made solutions to fit your requirements, request[emailprotected] https://www.futuremarketinsights.co/customization-available/REP-GB-6733

This report includes the estimation of market size for value (million USD) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Genetic Leukemia Detection Testing market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

See original here:
Genetic Leukemia Detection Testing Market Evenly Poised To Reach A Market Value Of US$ By 2018 2028 - 3rd Watch News

New York, July 11, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Direct-to-Consumer (DTC) Genetic Testing Industry" - https://www.reportlinker.com/p05442614/?utm_source=GNW 2 Billion in the year 2020, is projected to reach a revised size of US$3.8 Billion by 2027, growing at a CAGR of 18.5% over the analysis period 2020-2027.Ancestry & Relationship Testing, one of the segments analyzed in the report, is projected to grow at a 18.4% CAGR to reach US$1.6 Billion by the end of the analysis period.After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Carrier Testing segment is readjusted to a revised 19% CAGR for the next 7-year period. This segment currently accounts for a 20% share of the global Direct-to-Consumer (DTC) Genetic Testing market.

The U.S. Accounts for Over 26.9% of Global Market Size in 2020, While China is Forecast to Grow at a 23.9% CAGR for the Period of 2020-2027 The Direct-to-Consumer (DTC) Genetic Testing market in the U.S. is estimated at US$310.1 Million in the year 2020. The country currently accounts for a 26.9% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$900.9 Million in the year 2027 trailing a CAGR of 23.7% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 13.2% and 16.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 14.6% CAGR while Rest of European market (as defined in the study) will reach US$900.9 Million by the year 2027.

Predictive Testing Segment Corners a 15.5% Share in 2020 In the global Predictive Testing segment, USA, Canada, Japan, China and Europe will drive the 21.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$133.8 Million in the year 2020 will reach a projected size of US$528.5 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$599.6 Million by the year 2027, while Latin America will expand at a 25% CAGR through the analysis period. We bring years of research experience to this 17th edition of our report. The 327-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

-Competitors identified in this market include, among others,

Read the full report: https://www.reportlinker.com/p05442614/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Genetic Testing: A Synopsis Recent Market Activity Direct-to-Consumer (DTC) Genetic Testing: An Overview Major Factors Impacting DTC Genetic Testing Market Regulatory Restrictions and Privacy Concerns - Major Dampeners for DTC Genetic Testing Consumers Self-Managing Treatments: The New Trend Authorities Grappling With Setting Appropriate Regulations for DTC Genetic Testing Changing Landscape of DTC Genetic Testing Regulations to Determine Market Viability Potential Benefits Outweigh Concerns DTC Genetic Testing: High Potential Benefits, But Concerns Persist Quality Assurance Confidentiality of Genetic Information Price and Related Services Greater Chances of Misinterpretation Regulatory Headwinds and Data Paucity Impacting DTC Genetic Testing Market Despite Progress in DTC Genetic Testing Regulations, Concerns Still Linger Transparency of Data: Bugbear of DTC Genetic Testing Companies The Contextual Privacy Conundrum Increasing Adoption Raises the Threat of Data Breach DTC Genetic Testing Companies - An Unregulated Lot Association for Molecular Pathology v. Myriad Genetics, Inc. Ruling Removes Potential Barriers for DTC Genetic Testing Companies Competitive Scenario Recent Transactions in DTC Genetics Testing Market Global Competitor Market Shares Direct-to-Consumer (DTC) Genetic Testing Competitor Market Share Scenario Worldwide (in %): 2020 & 2029 Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS 23andMe, Inc. (USA) Ancestry.com, LLC (USA) Any Lab Test Now (USA) Color Genomics, Inc. (USA) Counsyl, Inc. (USA) Direct Laboratory Services, LLC (USA) Gene by Gene, Ltd. (USA) Laboratory Corporation of America Holdings (USA) Mapmygenome India Limited (India) Positive Bioscience, Inc. (India) Quest Diagnostics, Inc. (USA) Request A Test, Ltd. (USA) Sonora Quest Laboratories LLC (USA) Xcode Life Sciences (India)

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE Table 1: Direct-to-Consumer (DTC) Genetic Testing Global Market Estimates and Forecasts in US$ Thousand by Region/Country: 2020-2027

Table 2: Direct-to-Consumer (DTC) Genetic Testing Global Retrospective Market Scenario in US$ Thousand by Region/Country: 2012-2019

Table 3: Direct-to-Consumer (DTC) Genetic Testing Market Share Shift across Key Geographies Worldwide: 2012 VS 2020 VS 2027

Table 4: Ancestry & Relationship Testing (Test Type) World Market by Region/Country in US$ Thousand: 2020 to 2027

Table 5: Ancestry & Relationship Testing (Test Type) Historic Market Analysis by Region/Country in US$ Thousand: 2012 to 2019

Table 6: Ancestry & Relationship Testing (Test Type) Market Share Breakdown of Worldwide Sales by Region/Country: 2012 VS 2020 VS 2027

Table 7: Carrier Testing (Test Type) Potential Growth Markets Worldwide in US$ Thousand: 2020 to 2027

Table 8: Carrier Testing (Test Type) Historic Market Perspective by Region/Country in US$ Thousand: 2012 to 2019

Table 9: Carrier Testing (Test Type) Market Sales Breakdown by Region/Country in Percentage: 2012 VS 2020 VS 2027

Table 10: Predictive Testing (Test Type) Geographic Market Spread Worldwide in US$ Thousand: 2020 to 2027

Table 11: Predictive Testing (Test Type) Region Wise Breakdown of Global Historic Demand in US$ Thousand: 2012 to 2019

Table 12: Predictive Testing (Test Type) Market Share Distribution in Percentage by Region/Country: 2012 VS 2020 VS 2027

Table 13: Nutrigenomics Testing (Test Type) World Market Estimates and Forecasts by Region/Country in US$ Thousand: 2020 to 2027

Table 14: Nutrigenomics Testing (Test Type) Market Historic Review by Region/Country in US$ Thousand: 2012 to 2019

Table 15: Nutrigenomics Testing (Test Type) Market Share Breakdown by Region/Country: 2012 VS 2020 VS 2027

Table 16: Other Test Types (Test Type) World Market by Region/Country in US$ Thousand: 2020 to 2027

Table 17: Other Test Types (Test Type) Historic Market Analysis by Region/Country in US$ Thousand: 2012 to 2019

Table 18: Other Test Types (Test Type) Market Share Distribution in Percentage by Region/Country: 2012 VS 2020 VS 2027

Table 19: Single Nucleotide Polymorphism (SNP) Chips (Technology) World Market Estimates and Forecasts in US$ Thousand by Region/Country: 2020 to 2027

Table 20: Single Nucleotide Polymorphism (SNP) Chips (Technology) Market Worldwide Historic Review by Region/Country in US$ Thousand: 2012 to 2019

Table 21: Single Nucleotide Polymorphism (SNP) Chips (Technology) Market Percentage Share Distribution by Region/Country: 2012 VS 2020 VS 2027

Table 22: Targeted Analysis (Technology) Market Opportunity Analysis Worldwide in US$ Thousand by Region/Country: 2020 to 2027

Table 23: Targeted Analysis (Technology) Global Historic Demand in US$ Thousand by Region/Country: 2012 to 2019

Table 24: Targeted Analysis (Technology) Market Share Distribution in Percentage by Region/Country: 2012 VS 2020 VS 2027

Table 25: Whole Genome Sequencing (WGS) (Technology) World Market by Region/Country in US$ Thousand: 2020 to 2027

Table 26: Whole Genome Sequencing (WGS) (Technology) Historic Market Analysis by Region/Country in US$ Thousand: 2012 to 2019

Table 27: Whole Genome Sequencing (WGS) (Technology) Market Share Breakdown of Worldwide Sales by Region/Country: 2012 VS 2020 VS 2027

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES Market Facts & Figures US Direct-to-Consumer (DTC) Genetic Testing Market Share (in %) by Company: 2020 & 2025 Market Analytics Table 28: United States Direct-to-Consumer (DTC) Genetic Testing Market Estimates and Projections in US$ Thousand by Test Type: 2020 to 2027

Table 29: Direct-to-Consumer (DTC) Genetic Testing Market in the United States by Test Type: A Historic Review in US$ Thousand for 2012-2019

Table 30: United States Direct-to-Consumer (DTC) Genetic Testing Market Share Breakdown by Test Type: 2012 VS 2020 VS 2027

Table 31: Direct-to-Consumer (DTC) Genetic Testing Market in US$ Thousand in the United States by Technology: 2020-2027

Table 32: United States Direct-to-Consumer (DTC) Genetic Testing Market Retrospective Analysis in US$ Thousand by Technology: 2012-2019

Table 33: United States Direct-to-Consumer (DTC) Genetic Testing Market Share Breakdown by Technology: 2012 VS 2020 VS 2027

CANADA Table 34: Canadian Direct-to-Consumer (DTC) Genetic Testing Market Estimates and Forecasts in US$ Thousand by Test Type: 2020 to 2027

Table 35: Canadian Direct-to-Consumer (DTC) Genetic Testing Historic Market Review by Test Type in US$ Thousand: 2012-2019

Table 36: Direct-to-Consumer (DTC) Genetic Testing Market in Canada: Percentage Share Breakdown of Sales by Test Type for 2012, 2020, and 2027

Table 37: Direct-to-Consumer (DTC) Genetic Testing Market Analysis in Canada in US$ Thousand by Technology: 2020-2027

Table 38: Direct-to-Consumer (DTC) Genetic Testing Market in Canada: Historic Review in US$ Thousand by Technology for the Period 2012-2019

Table 39: Canadian Direct-to-Consumer (DTC) Genetic Testing Market Share Breakdown by Technology: 2012 VS 2020 VS 2027

JAPAN Table 40: Japanese Market for Direct-to-Consumer (DTC) Genetic Testing: Annual Sales Estimates and Projections in US$ Thousand by Test Type for the Period 2020-2027

Table 41: Direct-to-Consumer (DTC) Genetic Testing Market in Japan: Historic Sales Analysis in US$ Thousand by Test Type for the Period 2012-2019

Table 42: Japanese Direct-to-Consumer (DTC) Genetic Testing Market Share Analysis by Test Type: 2012 VS 2020 VS 2027

Table 43: Japanese Medium & Long-Term Outlook for Direct-to-Consumer (DTC) Genetic Testing Market in US$ Thousand by Technology: 2020-2027

Table 44: Direct-to-Consumer (DTC) Genetic Testing Market in Japan in US$ Thousand by Technology: 2012-2019

Table 45: Japanese Direct-to-Consumer (DTC) Genetic Testing Market Percentage Share Distribution by Technology: 2012 VS 2020 VS 2027

CHINA Table 46: Chinese Direct-to-Consumer (DTC) Genetic Testing Market Growth Prospects in US$ Thousand by Test Type for the Period 2020-2027

Table 47: Direct-to-Consumer (DTC) Genetic Testing Historic Market Analysis in China in US$ Thousand by Test Type: 2012-2019

Table 48: Chinese Direct-to-Consumer (DTC) Genetic Testing Market by Test Type: Percentage Breakdown of Sales for 2012, 2020, and 2027

Table 49: Direct-to-Consumer (DTC) Genetic Testing Market Estimates and Forecasts in China in US$ Thousand by Technology: 2020-2027

Table 50: Chinese Direct-to-Consumer (DTC) Genetic Testing Retrospective Market Scenario in US$ Thousand by Technology: 2012-2019

Table 51: Direct-to-Consumer (DTC) Genetic Testing Market in China: Percentage Share Analysis by Technology for 2012, 2020, and 2027

EUROPE Market Facts & Figures European Direct-to-Consumer (DTC) Genetic Testing Market: Competitor Market Share Scenario (in %) for 2020 & 2025 Market Analytics Table 52: European Direct-to-Consumer (DTC) Genetic Testing Market Demand Scenario in US$ Thousand by Region/Country: 2020-2027

Table 53: Direct-to-Consumer (DTC) Genetic Testing Market in Europe: A Historic Market Perspective in US$ Thousand by Region/Country for the Period 2012-2019

Table 54: European Direct-to-Consumer (DTC) Genetic Testing Market Share Shift by Region/Country: 2012 VS 2020 VS 2027

Table 55: European Direct-to-Consumer (DTC) Genetic Testing Market Estimates and Forecasts in US$ Thousand by Test Type: 2020-2027

Table 56: Direct-to-Consumer (DTC) Genetic Testing Market in Europe in US$ Thousand by Test Type: A Historic Review for the Period 2012-2019

Table 57: European Direct-to-Consumer (DTC) Genetic Testing Market Share Breakdown by Test Type: 2012 VS 2020 VS 2027

Table 58: European Direct-to-Consumer (DTC) Genetic Testing Market Assessment in US$ Thousand by Technology: 2020-2027

Table 59: European Direct-to-Consumer (DTC) Genetic Testing Historic Market Review in US$ Thousand by Technology: 2012-2019

Table 60: Direct-to-Consumer (DTC) Genetic Testing Market in Europe: Percentage Breakdown of Sales by Technology for 2012, 2020, and 2027

FRANCE Table 61: Direct-to-Consumer (DTC) Genetic Testing Market in France by Test Type: Estimates and Projections in US$ Thousand for the Period 2020-2027

Table 62: French Direct-to-Consumer (DTC) Genetic Testing Historic Market Scenario in US$ Thousand by Test Type: 2012-2019

Table 63: French Direct-to-Consumer (DTC) Genetic Testing Market Share Analysis by Test Type: 2012 VS 2020 VS 2027

Table 64: French Direct-to-Consumer (DTC) Genetic Testing Market Estimates and Projections in US$ Thousand by Technology: 2020-2027

Table 65: French Direct-to-Consumer (DTC) Genetic Testing Historic Market Analysis in US$ Thousand by Technology: 2012-2019

Table 66: French Direct-to-Consumer (DTC) Genetic Testing Market Share Breakdown by Technology: 2012 VS 2020 VS 2027

GERMANY Table 67: Direct-to-Consumer (DTC) Genetic Testing Market in Germany: Recent Past, Current and Future Analysis in US$ Thousand by Test Type for the Period 2020-2027

Table 68: German Direct-to-Consumer (DTC) Genetic Testing Historic Market Analysis in US$ Thousand by Test Type: 2012-2019

Table 69: German Direct-to-Consumer (DTC) Genetic Testing Market Share Breakdown by Test Type: 2012 VS 2020 VS 2027

Table 70: German Direct-to-Consumer (DTC) Genetic Testing Latent Demand Forecasts in US$ Thousand by Technology: 2020-2027

Table 71: Direct-to-Consumer (DTC) Genetic Testing Market in Germany: A Historic Perspective by Technology in US$ Thousand for the Period 2012-2019

Table 72: German Direct-to-Consumer (DTC) Genetic Testing Market Share Breakdown by Technology: 2012 VS 2020 VS 2027

ITALY Table 73: Italian Direct-to-Consumer (DTC) Genetic Testing Market Growth Prospects in US$ Thousand by Test Type for the Period 2020-2027

Table 74: Direct-to-Consumer (DTC) Genetic Testing Historic Market Analysis in Italy in US$ Thousand by Test Type: 2012-2019

Table 75: Italian Direct-to-Consumer (DTC) Genetic Testing Market by Test Type: Percentage Breakdown of Sales for 2012, 2020, and 2027

Table 76: Direct-to-Consumer (DTC) Genetic Testing Market Estimates and Forecasts in Italy in US$ Thousand by Technology: 2020-2027

Table 77: Italian Direct-to-Consumer (DTC) Genetic Testing Retrospective Market Scenario in US$ Thousand by Technology: 2012-2019

Table 78: Direct-to-Consumer (DTC) Genetic Testing Market in Italy: Percentage Share Analysis by Technology for 2012, 2020, and 2027

UNITED KINGDOM Table 79: United Kingdom Market for Direct-to-Consumer (DTC) Genetic Testing: Annual Sales Estimates and Projections in US$ Thousand by Test Type for the Period 2020-2027

Table 80: Direct-to-Consumer (DTC) Genetic Testing Market in the United Kingdom: Historic Sales Analysis in US$ Thousand by Test Type for the Period 2012-2019

Table 81: United Kingdom Direct-to-Consumer (DTC) Genetic Testing Market Share Analysis by Test Type: 2012 VS 2020 VS 2027

Table 82: United Kingdom Medium & Long-Term Outlook for Direct-to-Consumer (DTC) Genetic Testing Market in US$ Thousand by Technology: 2020-2027

Table 83: Direct-to-Consumer (DTC) Genetic Testing Market in the United Kingdom in US$ Thousand by Technology: 2012-2019

Table 84: United Kingdom Direct-to-Consumer (DTC) Genetic Testing Market Percentage Share Distribution by Technology: 2012 VS 2020 VS 2027

SPAIN Table 85: Spanish Direct-to-Consumer (DTC) Genetic Testing Market Estimates and Forecasts in US$ Thousand by Test Type: 2020 to 2027

Table 86: Spanish Direct-to-Consumer (DTC) Genetic Testing Historic Market Review by Test Type in US$ Thousand: 2012-2019

Table 87: Direct-to-Consumer (DTC) Genetic Testing Market in Spain: Percentage Share Breakdown of Sales by Test Type for 2012, 2020, and 2027

Table 88: Direct-to-Consumer (DTC) Genetic Testing Market Analysis in Spain in US$ Thousand by Technology: 2020-2027

Read the original here:
Global Direct-to-Consumer (DTC) Genetic Testing Industry - GlobeNewswire

Heart failure impacts between three to four per cent of the general population. While commonly related to heart attacks it can also be due to a condition called dilated cardiomyopathy (DCM), a disease characterized by an enlarged and weak heart muscle that cant efficiently pump blood.

An international, multi-centre study led by Dr. James White, MD, a clinician and researcher at the University of Calgarys Cumming School of Medicine (CSM), has revealed magnetic resonance imaging (MRI) can be used to predict major cardiac events for people diagnosed with DCM.

Whites study, published in Circulation Cardiovascular Imaging, confirms about 40 per cent of patients with DCM have scarring patterns on their heart muscle which can be seen with MRI. These patterns are associated with higher risk of future heart failure admissions, life-threatening heart rhythms and death.

The study, which was the largest ever conducted using MRI in patients with DCM, also shows that cardiac MRI can play an important role in guiding the care of individual patients with heart failure, an approach called personalized medicine. The results of this study could lead to trials looking at how patients at higher risk may benefit from more intensive treatments. White says that treating patients with DCM is challenging because there is a lack of understanding into what causes the disease and why patients respond differently to the available treatments.

We have tended to think of dilated cardiomyopathy as one type of heart disease and that all patients should respond the same way, but we are learning that it is a collection of disease states that affect each patient differently, says White, explaining those that dont respond well to treatments are more prone to cardiac arrest, which kills about 35,000 Canadians annually.

The purpose of our study was to see if we could find individual patient features that can help us prescribe life-saving therapies, such as the ICD (implantable cardioverter defibrillator).

White and his team assembled the MINICOR (Multimodal International Cardiovascular Outcomes Registry) group, which involves 12 centres from Canada, the United States, Spain and Italy, to provide researchers access to highly standardized data collected from patients around the world with the goal of promoting personalized care for patients with cardiovascular disease.

We can have a much greater impact on patient care and on clinical practice in general when we work together, says White The true benefit of initiatives like this is our ability to test innovative ideas quickly and show they can work in different health-care systems and patient populations. This is the unique power of multi-national collaborations.

White and his team of data scientists and students are currently tracking the health of more than 10,000 Albertans who have undergone cardiac MRI.With this data they are developing new approaches to deliver personalized risk prediction models for patients with cardiovascular disease.

Libin Institute director Dr. Paul Fedak, MD, PhD, is excited about the potential of this project and its alignment with the institutes aim to lead in the area of precision cardiovascular medicine.

These are important steps towards personalizing care decisions for individual patients, says Fedak. We are constantly being reminded that the more we know about each patient and their own disease, the better we can make decisions to improve their health.

James Whiteis a professor in the departments of Cardiac Sciences, Radiology and Medicine and a member of the Libin Cardiovascular Institute at the Cumming School of Medicine.

James White led an international study on heart failure. Here, he stands in front of the cardiac MRI machine in the Stephenson Cardiac Imaging Centre.

Britton Ledingham for Libin Cardiovascular Institute

Read the rest here:
Researcher leads international study of patients at risk of heart failure and death - UCalgary News

Global Companion Diagnostics Market was valued US$ 2.68 Bn in 2017 and is expected to reach US$ 10.76 Bn by 2026, at a CAGR of 18.98 % during a forecast period.

A diagnostic is a process of determining disease, condition, and illness, which clarifies a person symptoms & signs that is useful for an individuals treatment. Companion diagnostic is a medical device that provides important information required for the safety & effective use of a biological product. Companion diagnostics are majorly used in the oncology area due to the growing incidence of cancer and it improvers the focus on cancer research.

The important driving factors of the global companion diagnostics market are the rising demand for targeted therapy and the increasing prevalence of cancer. Rising awareness of personalized medicines, growing cases of adverse drug reactions, and co-development of drug & diagnostic technology is also boosting the growth market.

Request For Report sample @ https://www.trendsmarketresearch.com/report/sample/5712

Increasing demand for next-generation sequencing and emerging applications of companion diagnostics in oncology indication provides key opportunities for companion diagnostics market. However, high cost involved in the development of therapeutics & diagnostic tests, and issues related to intellectual property rights is limiting the market growth.

The assay kits & reagents segment accounted for the largest share in the market, owing to its wide range of applications in platforms such as PCR, NGS, IHC, and ISH. Polymerase chain reaction (PCR) is a method widely used in molecular biology to make many copies of a specific DNA segment and is occupied the largest share during the forecast period.

Next-generation sequencing (NGS) is the technology that is used to arrange millions of small fragments of DNA in a line at the same time NGS are capable of processing multiple DNA sequences in parallel. NGS is expected to grow at a high CAGR during the forecast period owing to the availability of next-generation sequencing at low cost, technological advancements and high prevalence of cancer cases.

The supportive government initiatives to promote precision medicine research, along with the strategic alliances between key market players for companion diagnostics test development is expected to hold the largest share in North America followed by Europe throughout the forecast period. Increasing technological advancements aimed at developing companion diagnostic tests for new indications such as neurology, infectious diseases are also expected to hold the largest share in this region. Europe is rising demand for efficiency in healthcare & strengthening healthcare system and Germany is the largest market in Europe due to the presence of major market players and growing demand for technological advancement in these regions. However, Middle East & Africa are estimated to have a limited but stable growth owing to low healthcare expenditure and demand for primary healthcare services in this region.

Key player operating in the global companion diagnostics market are Abbott Laboratories, Agilent Technologies, Inc., ARUP Laboratories, BioMrieux SA, Danaher Corporation, F. Hoffmann-La Roche AG, Illumina, Inc., Invivoscribe Technologies, Inc., MolecularMD Corporation, Myriad Genetics, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., ArcherDx, Inc., Exosome Diagnostics, Inc., NeoGenomics, Inc., MDxHealth, Inc., and NanoString Technologies, Inc.

Scope of Global Companion Diagnostics Market:

Global Companion Diagnostics Market, by Product and Service:

Assay kits & reagents

Software & service

Global Companion Diagnostics Market, by Technology:

In situ hybridization

Polymerase chain reaction

Immunohistochemistry

Next-generation sequencing

Other technologies

Global Companion Diagnostics Market, by Indications:

Oncology

Neurology

Infectious diseases

Other indications

Global Companion Diagnostics Market, by End-User:

Pharmaceutical & biopharmaceutical companies

Reference laboratories

Other end users

Global Companion Diagnostics Market, by Region:

North America

Europe

Asia-Pacific

South America

Middle East & Africa

Key Player Operating In the Global Companion Diagnostics Market:

Abbott Laboratories

Agilent Technologies, Inc.

ARUP Laboratories

BioMrieux SA

Danaher Corporation

F. Hoffmann-La Roche AG

Illumina, Inc.

Invivoscribe Technologies, Inc.

MolecularMD Corporation

Myriad Genetics, Inc.

QIAGEN N.V.

Thermo Fisher Scientific Inc.

ArcherDx, Inc.

Exosome Diagnostics, Inc.

NeoGenomics, Inc.

MDxHealth, Inc.

NanoString Technologies, Inc.

More Info of Impact Covid19 @ https://www.trendsmarketresearch.com/report/covid-19-analysis/5712

Read more from the original source:
Companion Diagnostics Market Insights on Scope the COVID-19 - 3rd Watch News

This year has truly been a tale of two markets. For a five-week period in the first quarter, downside momentum in the stock market tied to the coronavirus disease 2019 (COVID-19) pandemic was unlike anything we'd ever seen before. But over the past 3.5 months, Wall Street has undertaken its strongest rally in more than two decades.

If 2020 has taught investors anything, it's the power of long-term investing and sticking with your initial investment thesis, even if some pretty big hiccups present themselves.

It's also taught investors that you don't need to be rich to become rich in the stock market. If you have $5,000 in cash at your disposal that won't be needed to pay bills or for emergencies, then you have more than enough capital to put to work in some of the fastest-growing industries in the new bull market. Here are five industries you'd be smart to consider buying into right now with $5,000.

Image source: Getty Images.

If these industries were being presented in any particular order (which they aren't), cloud computing would likely be at the top of the list. Even before COVID-19 became a serious concern, we were already witnessing a steady transition toward remote and shared-work capabilities. COVID-19 simply provided a shot in the arm to facilitate this transformation even faster. In my mind, there's little question that cloud growth should consistently remain in the double-digits on an annual basis throughout this decade.

While there are no shortage of cloud service companies to choose from, e-commerce giant Amazon (NASDAQ:AMZN) might be the preferred stock to own. Amazon Web Services (AWS) operates as an infrastructure-as-a-service player, which is a fancy way of saying that it supplies small and medium-sized businesses with the tools necessary to form the building blocks of their cloud-based platform. In just a five-quarter stretch, AWS has grown from 11% of Amazon's total sales to 13.5% of total sales, while accounting for the lion's share of its operating income during the first quarter.

Make no mistake about it, high-margin cloud sales are going to generate insane amounts of cash flow for Amazon and other cloud-service providers.

Image source: Getty Images.

If there's such a thing as a no-brainer industry to buy, it's cybersecurity. No matter how well or poorly the U.S. and global economy are performing, hackers don't take time off. This makes the hardware and subscription protection services provided by cybersecurity companies an absolute necessity. And with more businesses pushing into the cloud than ever before, there's a growing need for more sophisticated security solutions.

Here, I continue to be a fan of what Palo Alto Networks (NYSE:PANW) is doing. In recent quarters, Palo Alto has deemphasized physical firewall products in favor of higher-margin subscription and support services. This will lead to more consistent revenue recognition and should help reduce what little client churn the company is contending with. And yes, it'll help improve operating margins over the long run, too.

Palo Alto has also diversified its product offerings through numerous bolt-on acquisitions. Look for the company to continue spending aggressively on innovation and inorganic growth to improve its cloud-protection market share.

Image source: Getty Images.

The cannabis industry gets a bit of a bad rap given that the bubble finally burst in pot stocks over the past 15 months. Supply issues to our north, high tax rates in select U.S. markets, and financing concerns throughout North America have coerced caution from investors.

But this is still an industry where tens of billions of dollars in sales are conducted annually in the black market. It's expected that these illicit channels will gradually give way to legal sales over time and offer the North American marijuana industry a double-digit growth opportunity throughout much of the 2020s.

An intriguing name to consider here is Green Thumb Industries (OTC:GTBI.F). Green Thumb is a multistate operator with 48 open dispensaries and licenses to open as many as 96 stores in a dozen states. Green Thumb is currently generating about two-thirds of its revenue from higher-margin derivatives, rather than dried cannabis flower, which is a big reason it looks to be on the cusp of recurring profitability.

Furthermore, Green Thumb has established a significant presence in Illinois, which opened its doors to recreational weed sales on Jan. 1, 2020, as well as Nevada, which has the potential to lead the nation in cannabis spending per-capita by mid-decade.

Image source: Getty Images.

Another industry that looks set to come into its own is the Internet of Things (IoT). By IoT, I'm talking about wireless devices that can communicate with other wireless devices, as well as data centers. Like marijuana, IoT was hyped up too quickly in the 2010s, but has now had time to mature. This growing focus on technology making our lives easier is bound to have a positive impact on IoT companies for years to come.

The name to watch here is NXP Semiconductors (NASDAQ:NXPI), which generated almost half of its revenue last year from the automotive industry, with industrial equipment, communications, and mobile comprising the remainder of sales in 2019. In particular, NXP is a leader in self-driving and sensor equipment used in a number of newer automobiles. Between 2018 and 2021, NXP expects to have delivered a compound annual growth rate of 7% to 10% (this includes 2021 as an estimate), which is outpacing the CAGR for the IoT auto market of 5% to 7% over this same time frame.

Additionally, don't overlook other growth drivers for NXP, such as mobile payment adoption, the rollout of 5G networks, and its scalability in industrial processing applications.

Image source: Getty Images.

Last, but not least, don't forget about the personalized medicine push. Anything that caters to individual patient needs, especially during a pandemic, is likely to see demand improve significantly over the long run.

As a perfect example, take a closer look at Teladoc Health (NYSE:TDOC), which provides telemedicine visits for patients. Not only are these virtual visits critical during the pandemic to ensure that sick people remain in their homes, but it's a considerably more convenient method of arranging a consultation with a physician. It also doesn't hurt that telemedicine visits tend to be cheaper for insurance providers.

During the pandemic-impacted first quarter, Teladoc reported an absurd 92% uptick in virtual visits, with its paying membership increasing by 61% to 43 million people in the United States. Visit-fee-only access increased by a whopping 89%, as well. Though there's little question that Teladoc Health will continue to lose money in the near-term as it enhances its platform and makes complementary acquisitions, it clearly has the tools necessary to become a major player in personalized health over the next decade.

See the article here:
Got $5,000? Buy Stocks in These 5 Industries Now - Motley Fool

The recently published research report entitled Global Leukapheresis Market sheds light on critical aspects of the market like market size estimations, company and market best practices, market dynamics, market segmentation, competitive landscaping and benchmarking, opportunity analysis, economic forecasting, industry-specific technology solutions, guideline analysis, and in-depth benchmarking of vendor offerings. The report provides a clear understanding of the current and future scenarios and trends of the global Leukapheresis market. The report tracks an array of important market-related aspects which can be listed as follows; the demand and supply chain, the competitive landscape, leading industries shares, profit margin, and profiles of leading companies of the global market.

This report takes into account the current and future impacts of COVID-19 on this industry and offers you an in-depth analysis of Global Trans Resveratrol Market.

DOWNLOAD FREE SAMPLE:https://www.magnifierresearch.com/report-detail/29634/request-sample

Competitive Analysis:

The section offers great insights such as market revenue and market share of the global Leukapheresis market. The report explains a competitive edge over players competitors. Leading as well as prominent players of the global market are broadly studied on the basis of key factors. The report offers a comprehensive analysis and accurate statistics on sales by the player for the period 2015-2020. The report includes the forecasts, analysis, and discussion of important industry trends, market size, market share estimates, and profiles of the leading industry players. Company profile section of players such as Asahi Kasei Medical, Fresenius, Haemonetics, Terumo BCT, STEMCELL Technologies, Macopharma, HemaCare, AllCells, StemExpress, Caltag Medsystem, ZenBio,

Product segment analysis:

Application segment analysis: Hospitals, Research Institute,

To comprehend global Leukapheresis market dynamics in the world mainly, the worldwide market is analyzed across major global regions: North America (United States, Canada, Mexico), Asia-Pacific (China, Japan, South Korea, India, Australia, Indonesia, Thailand, Malaysia, Philippines, Vietnam), Europe (Germany, France, UK, Italy, Russia, Rest of Europe), Central & South America (Brazil, Rest of South America), Middle East & Africa (GCC Countries, Turkey, Egypt, South Africa, Rest of Middle East & Africa)

Moreover, the report elaborates different internal and external factors of the global Leukapheresis market. It uses numerous graphical presentation techniques such as graphs, tables, charts, pictures, and flowcharts. The report further focuses on market dynamics, growth drivers, developing market segments, and the market growth curve based on past, present, and future market data. The up-to-date, complete product knowledge, end-users, industry growth will drive profitability and revenue. Various important factors such as market trends, revenue growth patterns market shares, and demand and supply are included in the market research report for every industry.

READ FULL REPORT:https://www.magnifierresearch.com/report/global-leukapheresis-market-size-status-and-forecast-2020-2026-29634.html

The Key Highlights of The Report:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Magnifier Research is a leading market intelligence company that sells reports of top publishers in the technology industry. Our extensive research reports cover detailed market assessments that include major technological improvements in the industry. Magnifier Research also specializes in analyzing hi-tech systems and current processing systems in its expertise. We have a team of experts that compile precise research reports and actively advise top companies to improve their existing processes. Our experts have extensive experience in the topics that they cover. Magnifier Research provides you the full spectrum of services related to market research, and corroborate with the clients to increase the revenue stream, and address process gaps.

Contact UsMark StoneHead of Business DevelopmentPhone:+1-201-465-4211Email:[emailprotected]Web:www.magnifierresearch.com

Original post:
Global Leukapheresis Market 2020 Analysis, Types, Applications, Forecast and COVID-19 Impact Analysis 2026 - 3rd Watch News

ABC Health

Updated:10/07/202017:28h

save

Spanish researchers have seen that a fat stem cell therapy improves the prognosis in patients with Covid-19. The research, which has just been published in ClinicalMedicine, magazine that belongs to the group The Lancet, shows that a cell therapy with stem cells from adipose tissue for the treatment of critically ill patients covid-19, which has been applied through a compassionate use program, reduces 75% of treated patients inflammation and increases the activity of your immune system.

The patients included in this study have been treated in four Spanish centers: Fundacin Jimnez Daz, the Clnica Universidad de Navarra, the Hospital Universitario de Salamanca and the Hospital General Universitario Gregorio Maran.

Research has evaluated the tolerability and safety of administration to patients of adipose tissue-derived mesenchymal stem cells. Mesenchymal stem cells, known as multipotent cells, can differentiate into various cell types while maintaining a high capacity for renewal.

Those coming from adipose tissue cells (adipocytes) They have anti-inflammatory and immunomodulatory effects, are easily accessible and have a great capacity to expand also in the laboratory over long periods of time without losing their characteristics.

Advanced mesenchymal stem cell therapy is already approved for some inflammatory diseases. In turn, there is preclinical evidence that intravenous administration of this cell therapy in models of respiratory infection caused by viruses reduces lung damage. For this reason, together with the fact of the role of inflammation in the pathogenesis of lung damage associated with SARS-CoV-2, we think that this therapy could be a beneficial alternative for severe covid-19 patients , points out the Felipe Prosper, senior researcher at Up.

The research presents the results of a study in which cells have been treated for the first time mother mesenquimales Covid-19 patients undergoing mechanical ventilation. In our Cell Production units we have been able to store these stem cells and have them available to administer to the 13 patients participating in the study.

They were all in critical condition and they had previously received treatment with antivirals and anti-inflammatories, a therapeutic protocol that is currently being used to combat the disease, he explains. Francisco Fernndez-Avils, of the Gregorio Maran General University Hospital.

Patients received between one and three doses of these cells from healthy donors. Two weeks after the first dose, nine patients improved their clinical condition and seven were already extubated and out of the ICU. In no case did we observe any adverse effects related to treatment , confirms Fermn Snchez-Guijo, of the University Hospital of Salamanca and of Institute of Biomedical Research of Salamanca (IBSAL), and first signatory of the published work.

In this preliminary series of cases, the researchers observed a general improvement of ventilation, radiological and biological parameters of patients associated with this cell therapy. According to the experts, the results obtained in this study represent the basis for further progress in order to demonstrate whether this treatment is really effective in patients with covid-19 pneumonia.

The therapy already has the approval of the Spanish Agency for Medicines and Health Products (AEMPS) to carry out the phase 2 clinical trial whose objective will be to demonstrate the efficacy of the treatment against standard therapy.

This work is the first published study that includes a series of patients with severe Covid-19 pneumonia treated with this cell therapy. Currently, multiple studies have been started with stem cells in patients with covid-19 pneumonia, both in Spain and in other countries of the world, in which the use of various sources of stem cells such as bone marrow, fat, or placenta .

We are convinced that our results are particularly relevant as they support the performance of these studies, says the doctor. Damin Garca Olmo, from Jimnez Daz Foundation.

.

Read more here:
Fat stem cells improve prognosis in patients with Covid-19 ...

Autologous fat grafting and adipose-derived stem cells are two distinct entities with two different risk profiles, and should be regulated as such. Autologous fat grafting prepared with the additional step of stromal vascular fraction isolation is considered a form of "stem cell therapy" given the high concentration of stem cells found in stromal vascular fraction. Much ambiguity existed in the distinction between autologous fat grafting and stromal vascular fraction initially, in terms of both their biological properties and how they should be regulated. The market has capitalized on this in the past decade to sell unproven "stem cell" therapies to unknowing consumers while exploiting the regulatory liberties of traditional fat grafting. This led to a Draft Guidance from the U.S. Food and Drug Administration in 2014 proposing stricter regulations on fat grafting in general, which in turn elicited a response from plastic surgeons, who have safely used autologous fat grafting in the clinical setting for over a century. After a series of discussions, the U.S. Food and Drug Administration released its Final Guidance in November of 2017, which established clear distinctions between autologous fat grafting and stromal vascular fraction and their separate regulations. By educating ourselves on the U.S. Food and Drug Administration's final stance on fat grafting and stem cell therapy, we can learn how to navigate the regulatory waters for the two entities and implement their clinical use in a responsible and informed manner.

Read this article:
Making Sense of Stem Cells and Fat Grafting in Plastic ...

Georgetown, Kentucky, July 07, 2020 (GLOBE NEWSWIRE) -- Ecofibre Limited (Ecofibre, Company) (ASX:EOF, OTC-NASDAQ Intl Designation: EOFBF) is pleased to announce that the Lankenau Institute for Medical Research1 (LIMR) has begun patient enrollment in a Phase II clinical trial using Ananda Health hemp-derived CBD.

The purpose of this study is to assess the efficacy of a hemp-based cannabidiol (CBD) product, Ananda Health Spectrum gelcaps, on the severity and duration of chemotherapy-induced peripheral neuropathy (CIPN) among breast, colon, and ovarian cancer patients who received common types of neurotoxic chemotherapy.

Ecofibre and Ananda demonstrate their commitment to advancing the science of CBD with the launch of the Coala-T-CBD study2 (ClinicalTrials.gov Identifier: NCT04398446). The phase II clinical trial began enrolling patients at LIMR in June.

The debilitating condition, CIPN, is often chronic, compromising patients quality of life and limiting their ability to complete a full course of potentially life-saving treatments. Currently, there are no safe and effective medications to treat or prevent CIPN, but research in animals using CBD offers hope as a new treatment.

The Coala-T-CBD StudyTMis the first clinical trial positioned to translate this success to humans and is led by oncologist Dr. Marisa Weiss, the founder and chief medical officer of http://www.Breastcancer.org and Director of Breast Radiation Oncology and Breast Health Outreach at Lankenau Medical Center.

We are proud to be the first in the United States to study the impact of hemp-derived full spectrum CBD on CIPN, a condition that affects approximately 25-50% of pediatric and adult cancer patients undergoing neurotoxic chemotherapy, Weiss states. Among other milestones, the Coala-T-CBD StudyTMreceived an IND (investigational new drug) by the Food and Drug Administration (FDA) and will use Ananda softgels in the study protocol.

To our knowledge, this is the first phase II clinical trial using full-spectrum hemp extract for the treatment of CIPN to receive an FDA IND. This level of research is necessary to answer the global call from the medical community, patients, and regulatory bodies seeking effective treatment of this difficult, common chemotherapy side effect, says Weiss. The IND allows for Weiss team to conduct the highest-quality research using a randomized, double-blind, placebo-controlled clinical trial.

Ananda Health Research Portfolio

The FDA has publicly requested data on hemp-derived CBD regarding tolerability, drug interactions, toxicity, and dosing. Ecofibre responded early by investing an additional USD $1.8 million in research across several studies.

In 2019, the company published a peer-reviewed study3regarding the effects of low-dose CBD in chronic pain patients. The results demonstrated that low-dose CBD was well tolerated and improved pain, sleep, mood and opioid use.

The Coala-T-CBD StudyTMcontributes to Ecofibres growing clinical research portfolio of CBD use across age groups, populations, disease states, and doses. Importantly, the Coala-T-CBD StudyTMwill offer critical insights on the use of higher-dose CBD.

Ecofibres second phase II clinical trial4(ClinicalTrials.gov Identifier: NCT04436081) will evaluate moderate-dose CBD on agitation, sleep and mood in dementia patients. The moderate-dose study is currently pursuing its own FDA IND and expects patient enrollment in August.

Both the Coala-T-CBD StudyTMand the dementia study include comprehensive physician and laboratory analyses to determine the safety of moderate and higher-dose CBD.

In addition to its clinical trials in the U.S., Ecofibre will be supporting research on low-dose full spectrum CBD later this year in Australia.

Alex Capano, Ecofibres Chief Science Officer states, These studies will provide solutions for patients and contribute valuable data on the safety and efficacy of hemp CBD products. We understand the critical need for more sophisticated, rigorous research and are dedicated to closing those gaps.

Ecofibre CEO, Eric Wang adds, A core foundation for Ananda Health has been to support quality research for patient and practitioner education. Whilst the recent pandemic has created market uncertainty, the Company remains highly committed to its long-term investment to support our customers and the FDA in creating the knowledge base to inform better decisions for our industry.

We are pleased to work with such a high-quality group of researchers and physicians at LIMR. The Coala-T-CBD StudyTMwill provide ongoing updates and anticipates completion in 2022.

For more information on Ecofibre Limited, visitwww.ecofibre.com.

About EcofibreEcofibre is a provider of hemp products in the United States and Australia.

In the United States, the Company produces nutraceutical products for human and pet consumption, as well as topical creams and salves. See http://www.anandahemp.com and http://www.anandaprofessional.com.

In Australia, the Company produces 100% Australian grown and processed hemp food products including protein powders, de-hulled hemp seed and hemp oil. See http://www.anandafood.com.

The Company is also developing innovative hemp-based products in textiles and composite materials in partnership with TexInnovate in the United States. See http://www.hempblack.com.

The Company owns or controls key parts of the value chain in each business, from breeding, growing and production to sales and marketing. Our value proposition to customers is built on strong brands and quality products.

About Main Line Health

Main Line Health is a not-for-profit health system serving portions of Philadelphia and its western suburbs. At its core are four of the regions most respected acute care hospitalsLankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospitalas well as one of the nations premier facilities for rehabilitative medicine, Bryn Mawr Rehabilitation Hospital.

Main Line Health also includes the Lankenau Institute for Medical Research, a non-profit biomedical research organization on the campus of Lankenau Medical Center, dedicated to advancing an understanding of the causes of cancer, diabetes and heart disease to help improve diagnosis and treatment as well as prevention.

About Breastcancer.org

Breastcancer.org is a patient-centric resource for breast health and breast cancer information and support. Our research drives our ability to engage, educate, and empower people with breast cancer with expert information and dynamic peer support community to help them make the best decisions for their lives. The nonprofit organization was founded by breast oncologist Marisa C. Weiss, M.D. and born out of her conviction that women with breast cancer need more information and support than a physician visit can provide. Breastcancer.org receives more than 30 million visits each year. For more information about Breastcancer.org, please visit http://www.Breastcancer.org.

Read more here:
ECOFIBRE LIMITED Ananda Health products used in first FDA authorized clinical trial on hemp-derived CBD to treat chemotherapy induced peripheral...

Global Precision Medicine Software Market presents insights into the present and upcoming industry trends, enabling the readers to identify the products and services, hence driving the enlargement and effectiveness. The research report provides a comprehensive breakdown of all the major factors impacting the market on a global and regional scale, including drivers, constraints, intimidation, challenges, opportunities, and industry-specific trends. Further, the report cites global certainties and endorsements along with downstream and upstream analysis of leading players.

Get more information on Global Precision Medicine Software Market Research Report by requesting FREE Sample Copy @ https://www.globalmarketers.biz/report/others/2015-2027-global-precision-medicine-software-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/146709#request_sample

Major Players:

Abbott Laboratories(US)Syapse, Inc. (US)Roper Technologies(US)Sunquest Information Systems Inc. (US)Pfizer, Inc., Merck & Co., Inc.(US)N-of-One, Inc. (US)NantHealth, Inc. (US)LifeOmic Health, LLC (US)Fabric Genomics (US)Allscripts(US)GlaxoSmithKline plc(UK)Gene42, Inc. (Canada)Foundation Medicine, Inc. (US)Koninklijke Philips N.V. (Netherlands)PierianDx, Inc. (US)Translational Software, Inc. (US)Flatiron Health, Inc. (US)IBM Watson Group (US)Sanofi S.A.(France)Tempus Labs, Inc. (US)AstraZeneca plc(US)2bPrecise LLC (Israel)Qiagen(Germany)SOPHiA GENETICS SA (Switzerland)Human Longevity, Inc. (US)

Global Precision Medicine Software Market research reports enlargement rates and the market value based on market dynamics, growth factors. Complete knowledge is based on the newest innovation in business, opportunities, and trends. In addition to SWOT examination by key suppliers, the report contains an all-inclusive market analysis and major players landscape.

The regional segmentation covers:

Segmentation by Type:

Cloud-basedOn-premise

Segmentation by Application:

Healthcare providersResearch centers & Government institutesPharmaceutical & Biotechnology companiesOther end users

Do Inquiry Before Purchasing Report Here and Ask For Discount @: https://www.globalmarketers.biz/discount_inquiry/discount/146709

Report Objectives

Enquire Before Buying : https://www.globalmarketers.biz/report/others/2015-2027-global-precision-medicine-software-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/146709#inquiry_before_buying

Table of Content:

The Global Precision Medicine Software Market

Chapter 1: Precision Medicine Software Market Overview, Drivers, Restraints and Opportunities

Chapter 2: Precision Medicine Software Market Competition by Manufacturers

Chapter 3: Precision Medicine Software Production by Regions

Chapter 4: Production, By Types, Market share by Types

Chapter 5: Consumption, By Applications

Chapter 6: Comprehensive profiling and analysis of Manufacturers

Chapter 7: Manufacturing cost analysis

Chapter 8: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 9: Marketing Strategy Analysis, Distributors/Traders

Chapter 10: Precision Medicine Software Market Effect Factors Analysis

Chapter 11: Precision Medicine Software Market Forecast

Chapter 12: Conclusion of Precision Medicine Software Market

The Report has Tables and Figures Browse The Report Description and TOC @ https://www.globalmarketers.biz/report/others/2015-2027-global-precision-medicine-software-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/146709#table_of_contents

See the article here:
Global Precision Medicine Software Market Analysis and Forecast 2027- including drivers, constraints, intimidation, challenges, opportunities, and...

Sohankumar Motwani knows how its like to live with impaired vision.He was born premature and blind on his right eye.Despite his decreased ability to see, he developed an interest in technology when he first held a computer in second grade at Don Bosco Makati.What caught my attention back then was the fact that it wasnt just about playing games. Computers allowed you do so much morelearn, customize, and create, said Sohan.By this time, his dream was to pursue a Computer Science degree in college.However, at age 15, the vision on his left eye started to blur. The doctor said it was all because I was born premature, he recalled.Sohan, with the support of his Pakistani family who settled in the Philippines 40 years ago, underwent a total of five surgeries: three in the Philippines and two in India. He had to temporarily quit school.The attending doctors stated they had done everything they could. We even tried to seek further treatment in China, but we were advised there were no other possible solutions available, he shared.My parents warned me that I would not be able to live as normally as I was used to.Then came years of depression.It was like the end of the world for me, related Sohan. But the greatest thing that I have learnt all throughout my journey was acceptance.Naturally, there were a number of unanswered questions that greatly bothered me. But I needed to move on. If I did not learn to accept it, then I would not have been able to look for ways to move forward.After a two-year medical break, Sohan decided to finish high school. Don Bosco Makati willingly welcomed him back.Trying to pick up from where he left off was not easy. It was a change in lifestyle, he admitted. I used to work as I saw things, but now I have to work as I hear them.Sohan was able to overcome this great challenge with the assistance of non-government organization Resources for the Blind, which provided technology that converted all his textbooks to soft copies to be read aloud by text-to-speech functions.He graduated from Don Bosco Makati with the St. Dominic Savio Award in recognition for his dedication in completing and acing his secondary education. When it was time to decide for further studies, the Resources for the Blind recommended De La Salle-College of Saint Benilde for its inclusive approach.With additional encouragement from family and close friends, Sohan found his calling in the colleges Information Systems Program. I realized that it was actually more than what I was looking for, he beamed."If I did not learn to accept it, then I would not have been able to look for ways to move forward."When he first entered Benilde, his friends brought him around the campus. He familiarized himself despite his limited perception.Shortly thereafter, he completely lost his eyesight, but he can already navigate around the vicinity with his cane.Sohan believes that he was able to chase his dream with the backing from his family, friends, and professors who always ensured he was never behind in the lessons. I even had a mentor who personally met me once to twice a week to check how I was doing in class, he shared.Fully losing my eyesight was a really big adjustment from my end, but Benilde attuned quite well with me. The atmosphere was very warm and I was reminded once again that inclusion is in the colleges DNA because I really felt it firsthand.In his second year, Sohan started to work as the web developer for the Student Publication Office, which automatically granted him 50 percent scholarship plus an opportunity to enhance his skills in the field.Sohan and friends Mark Christian Yu and Anna Alexandra Nery then conceptualized and created SOHAN, a smart navigation app designed to assist the visually impaired.SOHAN is composed of three platforms: a mobile app that sets and reads the destination, a wearable device that follows unique patterns of vibrations for instructions, and a web app that allows the guardians to check the current location.It features chat messaging and emergency alerts for easier connectivity. The team has completed the prototype and is currently working on the official release to ensure the safety of the probable users.His devotion and passion led him to be a consistent Deans Lister. He graduated with Magna Cum Laude honors.Sohan currently works as the Software Engineer of homegrown food mobile app c. He is involved in their family business and is experimenting on a finance-related project with a friend as well.Today, Sohan can no longer see the colors. He cannot even decipher whether it is day or night. But there is no stopping someone fueled with a desire to learn, explore, and create.

COMMENT DISCLAIMER: Reader comments posted on this Web site are not in any way endorsed by Manila Standard. Comments are views by manilastandard.net readers who exercise their right to free expression and they do not necessarily represent or reflect the position or viewpoint of manilastandard.net. While reserving this publications right to delete comments that are deemed offensive, indecent or inconsistent with Manila Standard editorial standards, Manila Standard may not be held liable for any false information posted by readers in this comments section.

See more here:
Overcoming the odds: A visionary for the visually impaired - manilastandard.net

Roslyn Young-Daniels and M. Lindsay Kaplan, Opinion contributors Published 7:00 a.m. ET July 11, 2020 | Updated 8:05 a.m. ET July 11, 2020

Racism is a pandemic that threatens Black people. Lets use this moment to create a country that not only protects their lives, but helps them thrive.

The Trump administrations latest move to end the Affordable Care Act threatens to deprive millions of Americans of health coverage in the midst of a pandemic. Especially troubling is that dismantling the law would disproportionately harm Black people advancing racism precisely as we grapple with its shameful legacy.

We emphatically endorse the need to develop policies to dismantle the racist structure of policing as one means of saving Black lives.However, unless we create and put in place strategies to ensure their health, well-being and access to medical care, many Black people will continue to fall sick and die from preventable illnesses.

Over 50 years ago,Dr. Martin Luther King, Jr. pointed out that of all the forms of inequality, injustice in health is the most shocking and the most inhuman because it often results in physical death. Today there is ample data showing that African Americans are at higher risk than other for both developing illness and dying from it.

One of us, Roslyn Young-Daniels, founded Black Health Matters so people could learn from and speak to researchers, medical practitioners and representatives of pharmaceutical companies about diseases that particularly affect the Black community. This information raises awareness and empowers people to advocate for their own health and well-being.

However, it was a federal policy that made the work of Black Health Matters possible. Without the Affordable Care Act, which expanded the availability of health insurance and took many other steps that improved health care for under-served communities, no amount of information or advocacy would have helped people who could not get medical care.

Doctors and nurses on June 11, 2020, in West Covina, California.(Photo: Mark Ralston/ AFP via Getty Images)

As beneficial as the ACA has been, we know that much more work needs to be done, and that governmental policy is a powerful means to effect it. The Brookings Institution recently recommended that the 2021 White House invest in Black and Brown neighborhoods and in well-being thus eliminating deserts in health care. Policy advisers for both campaigns need to make Black health a priority in the next administration.

Shockingly, rather than developing a policy to aid the Black community when its need is so painfully evident to most, the Trump administration has pressed forward with its drive to eliminate the ACA during the COVID-19 pandemic though it is disproportionately killing Black, Brown and poor people and has caused many to lose the jobs that provided their health insurance.

COVID can't be quarantined: A coronavirus to-do list for the pandemic and beyond: First, open our eyes and hearts.

In contrast, former Vice President Joe Biden has already taken the initiative on Black health by proposing investments geared to ending racial health disparities. He would strengthen and reform the ACA, provide support for community health centers, create mental health parity, address poverty, pollution and other adverse social determinants of health, and invest in Historically Black Colleges and Universities and Minority Serving Institutions to build a diverse pipeline of health care professionals.

We would also recommend more study of diseases that particularly affect Black people, such as lupus, sickle cell anemia, diabetes and hypertension. In addition, we would like to see hospitals in Black neighborhoods that dont focus primarily on trauma, but provide a wide range of services including preventative medicine. Another policy initiative would ensure that discussions and legislation on reparations include remedies for Black health disparities resulting from the history of slavery.

In addition to the next presidents vision, Congress must pass laws that realize these aspirations. Americans of all colors increasingly understand that racism functions as a larger pandemic threatening the lives of Black people. This growing consensus should inspire our elected officials to transform the institutions that perpetuatesystemic racism that devalues the lives and health of Black people and results in their death on a daily basis.

Trump and health care: Imagine a world with a COVID-19 pandemic and without the Affordable Care Act. Trump does.

While this is not an easy task, neither is it impossible.

Policy is defined by the investments a society chooses to make, as Sherrilyn Ifill, President and Director-Counsel of the NAACP Legal Defense and Educational Fund, argued in Anna Deavere Smith's "Notes from the Field," a 2018 HBO special. Ifill added that it takes moments, kind of almost epic moments, to move us to change those choices. This is one of those moments. Lets take advantage of it to create an America that not only protects the lives of Black people, but helps them thrive. Because #BlackHealthMatters.

Roslyn Young-Daniels is president ofBlack Health Matters.M. Lindsay Kaplan is a professor of English at Georgetown University.

Autoplay

Show Thumbnails

Show Captions

Read or Share this story: https://www.usatoday.com/story/opinion/2020/07/11/black-health-covid-19-shown-matters-more-than-ever-column/5408759002/

Go here to see the original:
Black health matters. COVID has shown that improving care must be a national priority. - USA TODAY

Some of the sickest coronavirus patients could be injected with lab-made antibodies when they arrive in hospitalto help themfight off the disease, according to a government advisor.

Prof Peter Openshaw, who sits on Sage's nine-strong clinical information group, described biotech therapies currently being trialled as potentially "very exciting" treatments for Covid-19 patients.

The drugs, known as monoclonal antibodies, are based on antibodies produced by patients who have recovered from coronavirus, and are the first potential new medicines specifically designed to attack the virus.

Prof Openshaw said such treatments would result in antibodies circulating in a patient's bloodstream "within half an hour", unlike vaccines, which could take "weeks" to stimulate the body into producing a similar response.

"One particular benefit might be that it could prevent progression to the severe disease that is sometimes seen in people who present with initial respiratory symptoms," he said.

"Boosting their antibody levels as soon as they arrive in hospital could mean that they don't go on to develop all the severe complications that do happen in a minority of patients."

Prof Openshaw, who is a professor of experimental medicine at Imperial College London, said British scientists were now awaiting the results of human trials that showed the effect of injecting monoclonal antibodies into Covid-19 patients in hospitals.

Unlike drugs such as dexamethasone, the steroid, monoclonal antibodies have been specifically designed to attack the virus and can be given to patients much earlier in the course of the disease.

Two US pharma firms, Eli Lilly and Regeneron, launched the first safety studies of monoclonal antibodies therapies in humans last month.

Read more here:
Sickest coronavirus patients could be injected with lab-made antibodies to help fight off infection - Telegraph.co.uk

While more countries around the world continue to acknowledge the potential of CBD, the full biological effects of the cannabinoid are yet to be fully understood. However, some research demonstrates that CBD has anti-inflammatory and immunosuppressive properties.

But what does this mean for those that use CBD products, and who could potentially benefit from it?

CBD is one of the most common chemical compounds found in the cannabis plant. It is classed as a cannabinoid, along with Tetrahydrocannabinol (THC) and Cannabinol (CBN), and over a hundred other compounds in the plant. Cannabinoids are naturally occurring chemicals that have become known for their medicinal and wellness potential.

It is also clear that, in some cases, CBD might be used to treat particular diseases for which other available treatments have failed to be effective. Although we know that it produces effects in the central nervous system, in contrast to THC, which is psychoactive, CBD doesnt create the so-called high feeling.

In a nutshell, the immune system is the main defense our bodies have against diseases and other potentially damaging threats. When functioning properly, the immune system identifies and attacks intruders, such as bacteria, viruses, and parasites distinguishing them from our bodys healthy tissue.

Lymphocytes, or B cells and T cells, fight against antigens and they help the body to remember the once-beaten substances so that the next time the immune system can act quickly and effectively.

Despite the existence of the Endocannabinoid System only being confirmed by researchers in the 1990s, we already know that this system can play an important role in many bodily functions, including brain functions. Endocannabinoid receptors are expressed throughout the central nervous system, as well as in the human immune system.

Interactions between endocannabinoids and receptors are thought to influence mood, emotions, appetite, pain-sensation and memory, among other important physiological and cognitive processes. Phytocannabinoids (the most well-known are CBD and THC) interact with this system in similar ways to endocannabinoids.

According to research by James M. Nichols and Barbara L.F. Kaplan, it would appear that considering all the studies conducted on immune responses and inflammation, the data overwhelmingly demonstrate that CBD is immune suppressive and anti-inflammatory.While the definition of something being anti-inflammatory should be clear, CBD functioning as an immunosuppressant might require clarification.

As a potential immunosuppressant, CBD may reduce the immune systems inflammatory responses, promote apoptosis (cellular death), and prevent rapid cellular growth. In certain cases, these features may have a negative effect on a healthy humans immune system.

In addition, CBD exposure may also suppress the functions of cytokines, chemokines, and T cells all of which play an important role in immunodefense.

It has been suggested that CBD may have potential as an adjunct treatment for some autoimmune diseases.

An autoimmune disease is when the immune system begins to attack healthy cells, tissues, and organs. This can occur basically anywhere in the body, and it can result in particular body functions weakening and, in some cases, life-threatening conditions. The most common autoimmune diseases include Multiple Sclerosis (MS), Rheumatoid Arthritis, and Psoriasis.

Inflammation plays an important role in autoimmune diseases. As an anti-inflammatory,CBD might help the body to tackle the disease. In addition, CBDs immunosuppressive nature might be able to help it to deal with hyperactive immune systems that attack themselves.

Link:
How Does CBD Affect the Immune System and Autoimmune Disease? - The Cannabis Exchange

Hansa Biopharma has granted an exclusive license to Sarepta Therapeutics for developing and promoting a pretreatment aimed to make a gene therapy to treat muscular dystrophy available to people that are naturally resistant to the treatment.

Gene therapy can be used to treat genetic conditions by delivering a healthy copy of the faulty gene using harmless recombinant viruses. The adeno-associated virus (AAV) is one of the most commonly used in gene therapy, and the basis of Sarepta Therapeutics gene therapy technology.

However, up to 70% of people naturally carry neutralizing antibodies against AAV. This prevents the transfer of the healthy gene sequence and raises safety concerns for the patient. Swedish company Hansa Biopharma is developing a pretreatment called imlifidase that works to eliminate these neutralizing antibodies prior to gene therapy treatments.

Imlifidase is an enzyme from the bacterium Streptococcus pyogenes that breaks down the antibodies that are involved in generating an immune response against external pathogens, inhibiting their activity within hours after administration.

Imlifidase is completely unique in development, said Emanuel Bjorne, VP Business Development at Hansa Biopharma. There is no product in the market that has this mode of action.

Sarepta Therapeutics aims to use imlifidase to extend its gene therapies for Duchenne muscular dystrophy and Limb-girdle muscular dystrophy to those patients that are naturally resistant to the AAV vectors used to deliver these treatments. According to the agreement, Hansa will get 8.8M ($10M) upfront and is eligible for a total of 350M ($397M) in development, regulatory, and sales milestone payments, in addition to royalties to future sales.

Sarepta Therapeutics will conduct preclinical evaluation of imlifidase as a pretreatment for gene therapy with Hansa providing our imlifidase expertise to the collaboration, said Bjorne. If everything goes according to plan, the company will start a clinical study of imlifidase in combination with Sareptas gene therapy in the second half of next year.

In preclinical models, Hansas technology has been successful in clearing the antibodies that prevent the success of gene therapies. If successful, this could offer the potential of extending existing gene therapy treatments to patients who would otherwise not be able to benefit from them. Hansa Biopharma is also investigating the use of this drug as a way to prevent the rejection of transplanted organs, and to treat cancer and rare autoimmune conditions.

Antara Mazumdar is a computational biologist based in Groningen, The Netherlands. She is also a freelance science writer who writes about various areas of biological research. Prior to that, she studied biomedical science and bioinformatics in New Delhi, India. Outside of work, she enjoys organizing scientific and cultural events, singing and is a traveling enthusiast.

Link:
Hansa Biopharma Gets up to 350M to Make Gene Therapy Work in Resistant... - Labiotech.eu

It might be the next best thing to a coronavirus vaccine.

Scientists have devised a way to use the antibody-rich blood plasma of COVID-19 survivors for an upper-arm injection that they say could inoculate people against the virus for months.

Using technology thats been proven effective in preventing other diseases such as hepatitis A, the injections would be administered to high-risk healthcare workers, nursing home patients, or even at public drive-through sites potentially protecting millions of lives, the doctors and other experts say.

The two scientists who spearheaded the proposal an 83-year-old shingles researcher and his counterpart, an HIV gene therapy expert have garnered widespread support from leading blood and immunology specialists, including those at the center of the nations COVID-19 plasma research.

But the idea exists only on paper. Federal officials have twice rejected requests to discuss the proposal, and pharmaceutical companies even acknowledging the likely efficacy of the plan have declined to design or manufacture the shots, according to a Times investigation. The lack of interest in launching development of immunity shots comes amid heightened scrutiny of the federal governments sluggish pandemic response.

There is little disagreement that the idea holds promise; the dispute is over the timing. Federal health officials and industry groups say the development of plasma-based therapies should focus on treating people who are already sick, not on preventing infections in those who are still healthy.

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, said an upper-arm injection that would function like a vaccine is a very attractive concept.

However, he said, scientists should first demonstrate that the coronavirus antibodies that are currently delivered to patients intravenously in hospital wards across the country actually work. Once you show the efficacy, then the obvious next step is to convert it into an intramuscular shot.

But scientists who question the delay argue that the immunity shots are easy to scale up and should enter clinical trials immediately. They say that until theres a vaccine, the shots offer the only plausible method for preventing potentially millions of infections at a critical moment in the pandemic.

Beyond being a lost opportunity, this is a real head-scratcher, said Dr. Michael Joyner, a Mayo Clinic researcher who leads a program sponsored by the Food and Drug Administration to capitalize on coronavirus antibodies from COVID-19 survivors. It seems obvious.

The use of so-called convalescent plasma has already become widespread. More than 28,000 patients have already received the IV treatment, and preliminary data suggest that the method is safe. Researchers are also looking at whether the IV drip products would prevent new infections from taking root.

The antibodies in plasma can be concentrated and delivered to patients through a type of drug called immune globulin, or IG, which can be given through either an IV drip or a shot. IG shots have for decades been used to prevent an array of diseases; the IG shot that prevents hepatitis A was first licensed in 1944. They are available to treat patients who have recently been exposed to hepatitis B, tetanus, varicella and rabies.

Yet for the coronavirus, manufacturers are only developing an intravenous solution of IG.

Joyner told The Times that 600 COVID-19 survivors donating their plasma each day could, depending on donation volumes and concentrations, generate up to 5,000 IG shots. With millions of probable survivors in the United States, he said, capacity isnt a problem.

Plasma companies said theyve focused their efforts on an intervention for the sickest patients. Grifols, for example, said it has not developed a shot because it is pursuing a federally supported IV formula to treat patients already infected with a serious case of COVID-19, but the company acknowledged that an antibody injection would be a good choice for prevention.

Advocates for the immunity shots say businesses are reluctant to invest in a product that could soon be replaced by a vaccine, so the government should offer financial incentives to offset that risk. Billions of federal dollars are already being spent on vaccine research through Operation Warp Speed, and funding for an IG shot that could serve as a bridge to a vaccine would come with a relatively modest price tag, they say.

Antibodies are the most precious resource on the planet right now, next to air. We have the industry, the technology, and the know-how to produce a proven product, said Patrick Schmidt, the chief executive of FFF Enterprises, a major distributor of IG products in the United States.

The amount of money and resources going into a vaccine, with no guarantee it will work this could have saved lives by now.

::

The proposal for an injection approach to coronavirus prevention came from an immunization researcher who drew his inspiration from history.

Dr. Michael Oxman knew that, even during the 1918 flu pandemic, the blood of recovered patients appeared to help treat others. Since then, convalescent plasma has been used to fight measles and severe acute respiratory syndrome, or SARS, among other diseases.

Like other doctors, Oxman surmised that, for a limited time, the blood coursing through the veins of coronavirus survivors probably contains immune-rich antibodies that could prevent or help treat an infection.

On March 27, he and Dr. John Zaia, the director of City of Hopes Center for Gene Therapy, submitted a proposal to the federal Biomedical Advanced Research and Development Authority, or BARDA, urging the rollout of IG shots for first responders and members of other high-risk groups.

The agency granted $12.5 million to Grifols and $14.5 million to Emergent BioSolutions to produce plasma-based COVID-19 medicines in IV form drips, among more than 50 different biomedical partnerships to fight the pandemic. But the immunity shot proposal was rejected.

The pair followed up with a detailed proposal to conduct a clinical trial at UC San Diego. They believed injectable 5-milliliter vials of IG could be given quickly by minimally trained healthcare workers, offering at least two months of immunity to doctors and nurses, as well as residents of nursing homes, college dormitories and military submarines.

The submission was backed by four other infectious disease researchers and statisticians, but it was also rejected, records show.

A spokeswoman for BARDA told The Times that the agency had received thousands of submissions, and that while we are interested in the potential of [IG] for treatment and prevention, we are focused intently on treatments for hospitalized patients to save lives.

The strategy baffled Oxman and Zaia, who said the IG shots are a far more efficient delivery system that can potentially reach many more people.

Whats more, prophylactic shots would probably require far fewer antibodies than IV treatments, Joyner said. With IG shots, plasma donations could possibly go twice or even five times as far, he said.

If a second wave of the virus were to arrive before an effective vaccine, that stockpile would be all the more essential.

Oxman started focusing his attention on the key players in the industry the manufacturers who dominate the development of plasma drugs. He held weekly phone calls with Schmidt, the distributor; together, the two tried to persuade seven companies to produce the shots themselves and bring them to health agencies for testing. They were unsuccessful.

Takeda and CSL Behring, two large companies who co-lead the new CoVIg-19 Plasma Alliance to develop an IG product for IV drips, said their efforts are trained on the sickest. The IV formula represents the fastest path to reach patients, assuming the trial is successful, said Julie Kim, the head of the plasma-derived therapies business unit at Takeda.

Financial calculations may be another factor for companies. Intravenous plasma products are traditionally the main economic driver for the industry, supply experts said, in part because vaccines have replaced many short-term immunity shots over the years. The money-making antibodies are also far more diluted in intravenous drugs than in injectable ones, which boosts profit margins.

They charge a fortune off of intravenous drugs in the hospital. They dont want to devote the manufacturing plant to something that wont make oodles of money, said one infectious disease expert, who has advocated for coronavirus IG shots but asked not to be publicly identified.

Researchers also said industry executives have little incentive to produce the immunity shots for the coronavirus, given the possibility that a longer-lasting vaccine could replace it within a year.

Representatives for CSL, Takeda and Grifols all challenged that assertion.

The choice of one delivery method or another has no connection with the potential financial or pricing implications, a Grifols spokesman told The Times.

Throughout May, researchers and doctors at Yale, Harvard, Johns Hopkins, Duke and four University of California schools sent a barrage of letters to dozens of lawmakers. They held virtual meetings with health policy directors on Capitol Hill, but say they have heard no follow-up to date.

Dr. Arturo Casadevall, the chair of the National COVID-19 Convalescent Plasma Project, said he spoke to FDA officials who told him they do not instruct companies on what to produce. Casadevall told The Times that the leaders of the national project were very supportive of the need to develop an IG shot rapidly and that he believed it would be very helpful in stemming the epidemic.

Joyner, of the Mayo Clinic, said there are probably 10 million to 20 million people in the U.S. carrying coronavirus antibodies and the number keeps climbing. If just 2% of them were to donate a standard 800 milliliters of plasma on three separate occasions, their plasma alone could generate millions of IG shots for high-risk Americans.

At a hot-spot meatpacking plant, or at a mobile unit in the parking lot outside a mall trust me, you can get the plasma, Joyner said. This is not a biological problem nor a technology problem. Its a back-of-the-envelope intelligence problem.

The antibody injections, for now, do not appear to be a high priority for the government or the industry.

Grifols, on April 28 the same day that the U.S. topped 1 million confirmed coronavirus cases made a major product announcement that would expand its leadership in disease treatment with immunoglobulins.

The product was a new vial for IG shots to treat rabies.

More here:
An injection may block COVID-19, but feds have failed to act - Los Angeles Times

"Nice to meet you. And when were you saved?"

Umm I hesitated.

"I remember the exact date" he interjected while I was still thinking. "August 3, 1972!"

This was the date that he had attended a revival, felt a stirring, and "accepted Jesus as his personal Lord and Savior." He told me about this holy experience and then turned back to me, expecting me to now have an answer.

I wondered if I was to tell him about the year I started to attend church, or perhaps he wanted the date of my baptism - was that the day I was "saved"? Or perhaps I should cite the time I felt a call to ministry (the first time), the radical deconstruction of the first faith in college, the emergence of renewed faith formation in graduate school, or the second calling into ministry that I had now pursued, or the incredibly recent moment that I was introduced to theologians who possessed the language I had been seeking all my life???

I settled on the time of sensing a gravitation toward ministry and responded, "I guess it would be the summer of 1999?"

"Oh." He was bewildered. And because I could not offer a particular date, he was suspicious.

The idea of immediate and radical conversion has become quite prominent within the Christian tradition. Where one "was blind but now one sees," as the hymn goes. Where the "scales fall from the eyes" and the entire identity changes to the degree that it requests a new name - Saul to Paul. I do not intend to discount the power of experience to reshape and reform us instantly and drastically, but I think that the dominance of this image of conversion is more influenced by human desire for effortless change and convenient resolution rather than sincere reflection on the experience of human transformation.

When we look at the example of the conversion of Saul to Paul in Acts 9, even there we read that the story of the conversion was not instantaneous. Instead, Saul has a revelation, is blind for three days (symbolism), has a mentor assigned to him, and dwells within the learning community "for several days." This is the pace of the most prominent image of conversion within the tradition, and there is wisdom and grace with this image for us today.

Within the white church, there is a great awakening to the pervasive presence of racist ideas and racist power. White Christians are awakening to the power and reality of racism within America and also within the systems and structures of the church itself (white supremacy and substitutionary atonement theory are a hell of a toxic combination). While there is blessing in the revelation and the desire to repent and change (convert), this is certainly not the time to uphold an image of immediate conversion.

Instead, now is a time to remember the pace of conversion that is more common to lived experience and described in the journey of Saul to Paul. There is a revelation that cannot be dismissed, there is a time of blindness (of acknowledging that we do not see clearly), of listening to mentors (those who do see clearly), and a time of entering into community with those who are striving to live in a more faithful way. As white communities and white Christians are coming to understand the calling to anti-racist work and living, we must be clear about the process of this conversion and what it will require.

This is and will be a lengthy journey of conversion - there is much to understand, repent, heal, and transform within the body and within the nation. So let us hold the urgency of change before us, and the pace of conversion within us, that we may remain prepared and committed to the process of transformation.

The Rev. Chris McCreight is ordained in the Christian Church (Disciples of Christ) and currently serves as minister of the Hiram Christian Church and chaplain of Hiram College. He is on Twitter @revmccreight.

Go here to see the original:
The Pace of Conversion - Suburbanite

Just dont drink it full stop (Credits: Getty Images/iStockphoto)

People have reportedly been cracking their way into communal hand sanitiser stations so that they can drink the gel inside, which contains a potentially lethal mix of chemicals and alcohol.

Dispensers in places such as South Shields, South Tyneside have been broken into, with vandals putting the gel into bottles so it can be drunk.

These hand gel stations have been made with a view to helping people keep safe from coronavirus but while the gel can save lives and kill germs when applied externally, if consumed, hand sanitiser can be highly dangerous.

Worryingly, York-based company BusinessWaste.co.uk have been tasked with dgetting rid of thousands of damaged gel containers every week.

Director Mark Hall spoke to the Independent on the matter, saying: Its happening all over the place, pretty much everywhere. We take these away for councils and businesses, and were seeing so many damaged you wouldnt believe.

Visit our live blog for the latest updates: Coronavirus news live

Its mindless idiocy. This stuff is 80% proof with who knows what other chemicals inside. Do not drink it.

While actions like this suggest extreme foolishness or and/or terrible addiction in the perpetrators, it bears repeating that you should not under any circumstances drink hand sanitiser.

Not only is the alcohol content high enough for you to overdose before you even start to feel drunk, but the other chemicals that make up hand gel are not remotely fit for human consumption

As if that wasnt bad enough, theres often no way to tell exactly how toxic the ingredients of communal hand gels are.

According to Sciencenotes.org: Two types of alcohol are used in alcohol-based hand sanitisers. The most common type contains between 60% and 95% ethanol (ethyl alcohol or grain alcohol).

This type of hand sanitiser can get you buzzed or drunk, but its the equivalent to 120-proof liquor. In contrast, vodka is 80-proof.

The webpage adds: The other type of alcohol-based hand sanitiser contains isopropyl alcohol (isopropanol or rubbing alcohol).

This kind of alcohol is toxic and can cause brain damage, blindness, kidney damage, and liver damage.

However, the ingredient with the potential to be the most toxic will often be listed as just fragrance, because said scents are often made using petrochemicals.

So please, we implore you, do not drink hand sanitiser.

MORE: Warning ahead of second Saturday night at pubs after lockdown easing

MORE: Englands R rate creeping back up to 1 week after lockdown is eased

Follow Metro across our social channels, on Facebook, Twitter and Instagram.

Share your views in the comments below.

Read the original post:
Please don't drink hand sanitiser just because it has alcohol in it - Metro.co.uk

Global Mesenchymal Stem Cells market study presents an in-depth scenario Which is segmented according to manufacturers, product type, applications, and areas. This segmentation will provide deep-dive analysis of the Mesenchymal Stem Cells industry for identifying the growth opportunities, development trends and factors limiting the growth of the market. This report offers forecast market information based on previous and current Mesenchymal Stem Cells industry scenarios and growth facets. All the key regions covered in Mesenchymal Stem Cells report are North America, Europe, Asia-Pacific, South America, Middle East and Africa. The Mesenchymal Stem Cells market share and market outlook of each area from 2020-2027 are presented in this report. A deep study of Mesenchymal Stem Cells market dynamics can help the market aspirants in identifying the business opportunities which will lead to accumulation of revenue. This section can effectively determine the Mesenchymal Stem Cells risk and key market driving forces.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/3309

The Mesenchymal Stem Cells report is segmented to provide a clear and Precise view of the international Mesenchymal Stem Cells market statistics and market estimates. Mesenchymal Stem Cells report Information represented in the form of graphs, charts, and figures will show the Mesenchymal Stem Cells growth speed, volume, goal consumer analysis. This report introduces the significant data to all Mesenchymal Stem Cells industry aspirants which will facilitate useful business decisions.

Some of the major companies operating in the global mesenchymal stem cell market are EMD Millipore Corporation, Cell Applications, Inc., Cyagen Biosciences, Inc., Genlantis, Inc., Advanced Cell Technology Incorporated, Stemcell Technologies Inc., Celprogen, Inc., Stemedica Cell Technologies, Aastrom Biosciences and ScienCell Research Laboratories.

Key points covered in the report

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/3309

The Mesenchymal Stem Cells report cover following data points:

Part 1: This section enlists the global Mesenchymal Stem Cells marketplace Summary, covering the simple market introduction, market evaluation by kind, software, and regions. The major Mesenchymal Stem Cells producing areas include North America, Europe, Asia-Pacific, Middle-East, and Africa. Mesenchymal Stem Cells industry states and outlook (2020-2027) is introduced in this part. Additionally, Mesenchymal Stem Cells market dynamics stating the opportunities, market risk, and key driving forces are researched.

Part 2: This part covers Mesenchymal Stem Cells manufacturers profile based On their small business overview, product type, and program. Additionally, the sales volume, Mesenchymal Stem Cells product cost, gross margin analysis, and Mesenchymal Stem Cells market share of each participant is profiled in this report.

Part 3 and Part 4: This component presents the Mesenchymal Stem Cells competition Based on sales, earnings, and market share of every manufacturer. Part 4 covers the Mesenchymal Stem Cells market situation based on areas. Region-wise Mesenchymal Stem Cells sales and expansion (2015-2019) is analyzed in this report.

Part 5 and Part 6: These two sections cover the North America and Europes Mesenchymal Stem Cells industry by countries. Under this Mesenchymal Stem Cells earnings, market share of those countries like USA, Canada, and Mexico is supplied. Beneath Europe Mesenchymal Stem Cells report includes, the states such as Germany, UK, France, Russia, Italy, Russia and their sales and growth is covered.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/3309

Sales revenue and expansion for the regions like Asia-Pacific, South America, Middle East & Africa. The earnings and expansion in these areas are introduced within this Mesenchymal Stem Cells business report.

Part 10 and Part 11: This part depicts the Mesenchymal Stem Cells market Share, earnings, sales by product type and application. The Mesenchymal Stem Cells sales growth seen during 2012-2020 is covered in this report.

Associated with Mesenchymal Stem Cells economy (2020-2027) for each area. The sales channels such as direct and indirect Mesenchymal Stem Cells marketing, traders, distributors, and future trends are presented within this report.

Part 14 and Part 15: These components present Mesenchymal Stem Cells market crucial Research findings and conclusion, study methodology, and information sources are covered.

Therefore, Global Mesenchymal Stem Cells report is a whole blend covering all The very important market aspects.

See the rest here:
Sales of the Mesenchymal Stem Cells Market to Anticipated to Exceed US$ XX by2020 Bulletin Line - Bulletin Line

Global Hematologic Malignancies market Research presents a Comprehensive scenario Which can be segmented according to producers, product type, applications, and areas. This segmentation will provide deep-dive analysis of the Hematologic Malignancies business for identifying the growth opportunities, development tendencies and factors limiting the development of the marketplace. This report features forecast market information based on previous and present Hematologic Malignancies industry scenarios and growth facets. Each of the Essential regions coated in Hematologic Malignancies report are North America, Europe, Asia-Pacific, South America, Middle East and Africa. The Hematologic Malignancies market share and market prognosis of every region from 2020-2027 are presented within this report. A deep study of Hematologic Malignancies marketplace dynamics will help the market aspirants in identifying the business opportunities that will lead to accumulation of earnings. This segment can efficiently determine the Hematologic Malignancies hazard and key market driving forces.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=2635108&source=atm

The Hematologic Malignancies report is segmented to provide a clear and Precise view of this international Hematologic Malignancies market statistics and market quotes. Hematologic Malignancies report Information represented in the form of graphs, charts, and statistics will show the Hematologic Malignancies growth rate, volume, goal customer analysis. This report presents the significant data to all Hematologic Malignancies business aspirants which will facilitate useful business decisions.

The key players covered in this studyPfizer, Inc.F. Hoffmann-LA Roche ltdSanofi-AventisBristol-Myers Squibb CompanyAbbVie, Inc.Novartis AGGlaxoSmithKline PLCCelgene CorporationJohnson & Johnson Services, Inc.Takeda Pharmaceutical Company limited

Market segment by Type, the product can be split intoLeukemiaLymphomaMultiple MyelomaOthersMarket segment by Application, split intoChemotherapyRadiotherapyImmunotherapyStem Cell TransplantationOthers

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global Hematologic Malignancies status, future forecast, growth opportunity, key market and key players.To present the Hematologic Malignancies development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Hematologic Malignancies are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2635108&source=atm

The Hematologic Malignancies report cover following data points:

Part 1: This part enlists the global Hematologic Malignancies marketplace Overview, covering the simple market debut, market analysis by kind, applications, and areas. Hematologic Malignancies industry states and prognosis (2020-2027) is presented in this part. Additionally, Hematologic Malignancies market dynamics saying the chances, market risk, and key driving forces are studied.

Part 2: This part covers Hematologic Malignancies manufacturers profile based On their small business overview, product type, and application. Additionally, the sales volume, Hematologic Malignancies product price, gross margin analysis, and Hematologic Malignancies market share of every player is profiled in this report.

Part 3 and Part 4: This part presents the Hematologic Malignancies competition Based on earnings, earnings, and market share of each producer. Part 4 covers the Hematologic Malignancies market scenario based on regions. Region-wise Hematologic Malignancies sales and growth (2015-2019) is studied in this report.

America and Europes Hematologic Malignancies industry by countries. Under this Hematologic Malignancies revenue, market share of those nations like USA, Canada, and Mexico is provided. Under Europe Hematologic Malignancies report contains, the countries such as Germany, UK, France, Russia, Italy, Russia and their sales and growth is coated.

Part 7, Part 8 and Part 9: These 3 sections covers Hematologic Malignancies The earnings and expansion in these regions are presented in this Hematologic Malignancies industry report.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2635108&licType=S&source=atm

Part 10 and Part 11: This component depicts the Hematologic Malignancies marketplace Share, earnings, sales by product type and application. The Hematologic Malignancies sales growth seen during 2012-2020 is covered in this report.

Related to Hematologic Malignancies market (2020-2027) for every region. The sales channels including indirect and direct Hematologic Malignancies advertising, traders, distributors, and future trends are presented in this report.

Part 14 and Part 15: These components present Hematologic Malignancies market key Research findings and judgment, research methodology, and data sources are covered.

Therefore, Global Hematologic Malignancies report is a complete blend covering all The very important market aspects.

View original post here:
Hematologic Malignancies Market Analysis Focusing on the Key Issues Surrounding the Growth of the Industry and Further Develop Opportunities - 3rd...